FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Trigilio Jeffrey  (Last) (First) (Middle)  C/O CULLINAN ONCOLOGY, INC.  ONE MAIN STREET, SUITE 520					- <u>Cı</u>	Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [ CGEM ]  3. Date of Earliest Transaction (Month/Day/Year) 09/08/2021									relationship of Reporting Person(s) to Issuer eck all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  Chief Financial Officer				
(Street) CAMBR (City)	IDGE M	A tate)	02142 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
											7. Nature								
Date					e nth/Day/Year)		Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. ) 8)		Disposed Of (D) (Instr. 3, 4		r. 3, 4 and	Bene	rities ficially ed Followin	(D)	m: Direct or Indirect nstr. 4)	of Indirect Beneficial Ownership	
										v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock			09/08	8/2021				M		15,000	A	\$4.3	3	17,250		D			
Common Stock 09/08				09/08	/2021	2021			S <sup>(1)</sup>		5,487	D	\$27.8	3(2)	11,763		D		
Common Stock 09/08			3/2021	2021		S <sup>(1)</sup>		9,513	D	\$28.8	5(3)	2,250		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				6. Date Exercise Expiration Date (Month/Day/Ye		te	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivat Securit Benefic Owned Follow Report	ive ties cially ing ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$4.3	09/08/2021			М			15,000	(4)		10/28/2030	Common Stock	15,000	\$0.00	237	,891	D		

## **Explanation of Responses:**

- 1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
- 2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$27.40 to \$28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$28.40 to \$29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 4. 25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

## Remarks:

/s/ Jeffrey Trigilio

09/09/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.